Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

HC Wainwright & Co. Maintains Buy on Novavax, Lowers Price Target to $19

Author: Benzinga Newsdesk | March 01, 2024 08:30am
HC Wainwright & Co. analyst Vernon Bernardino maintains Novavax (NASDAQ:NVAX) with a Buy and lowers the price target from $35 to $19.

Posted In: NVAX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist